{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"35","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The percentage of patients with an objective response rate will be determined. The overall response will be based on response in each compartment (skin, blood, lymph nodes and viscera) using a global composite scoring system. Objective response is considered (CR) Complete Response (Complete disappearance of all clinical evidence of disease), CRu (Complete Response Unconfirmed), or (PR) Partial Response (Regression of measurable disease).","dispersionType":"95% Confidence Interval","groups":[{"description":"MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.\n\nMLN9708","id":"OG000","title":"MLN9708"}],"paramType":"NUMBER","populationDescription":"12 analyzable patients","reportingStatus":"POSTED","timeFrame":"Up to 24 months after initiation of study treatment","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of patients"}